Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Genomics Institute of the Novartis Research Foundation · Novartis (Switzerland) · +3 more institutions
Abstract
Wnt signaling is one of the key oncogenic pathways in multiple cancers, and targeting this pathway is an attractive therapeutic approach. However, therapeutic success has been limited because of the lack of therapeutic agents for targets in the Wnt pathway and the lack of a defined patient population that would be sensitive to a Wnt inhibitor. We developed a screen for small molecules that block Wnt secretion. This effort led to the discovery of LGK974, a potent and specific small-molecule Porcupine (PORCN) inhibitor. PORCN is a membrane-bound O-acyltransferase that is required for and dedicated to palmitoylation of Wnt ligands, a necessary step in the processing of Wnt ligand secretion. We show that LGK974…
Citation impact
- FWCI
- 25.57
- Percentile
- 100%
- References
- 47
Authors
36- JLJun LiuCorresponding
Genomics Institute of the Novartis Research Foundation
- SPShifeng Pan
Genomics Institute of the Novartis Research Foundation
- MHMindy H. Hsieh
Genomics Institute of the Novartis Research Foundation
- NNNicholas Ng
Genomics Institute of the Novartis Research Foundation
- FSFangxian Sun
Genomics Institute of the Novartis Research Foundation
Topics & keywords
- Porcupine
- Wnt signaling pathway
- Cancer
- Biology
- Ecology
- Cell biology
- Genetics
- Good health and well-being